Cosmos Health Inc. (COSM): M&A transaction — Cosmos Health completes Cana buy for $1.67M; assets valued over $10M, expects gain

Cosmos Health Inc.

Purchase price $1.67M (€800k cash + $800k stock at $17.25/share) for 100% of Cana; closed June 30, 2023.
Cana's tangible and intangible assets independently valued >$10M; Cosmos expects substantial gain on bargain purchase.
Cana's 54,000 sq ft production facility added; prior acquisitions: Bikas GP (>$10M annual revenue) and ZipDoctor.
Binding LOI for German-based Docpharm; projected to add $30M annual revenue by 2025.
R&D clinical trials for obesity/weight management scheduled to start Q4 2023.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Cosmos Health Inc. completed an acquisition involving Pharmaceutical Laboratories CANA, S.A. for approximately $1.67 million (closed 2023-06-30).

Action: acquisition
Counterparty: Pharmaceutical Laboratories CANA, S.A.
Consideration: approximately $1.67 million
Closing: 2023-06-30

Exact text from the filing

On June 30, 2023, Cosmos Health Inc. (the “Company”) completed the acquisition of one hundred (100%) percent of the equity of Pharmaceutical Laboratories CANA, S.A. (“Cana Holdings”). The Purchase Price for the shares was approximately $1.67 million consisting of €800,000 in cash and $800,000 in stock, based on an issuance price of $17.25 per share.

View on SEC.gov

5 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Cosmos Health Inc. filing history →

Source: SEC EDGAR

accession 0001477932-23-005042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.